Prevent Effects of *Lactobacillus Fermentum* HY01 on Dextran Sulfate Sodium-Induced Colitis in Mice

Xiaoyong Chen, Xin Zhao, Hongwei Wang, Zelin Yang, Jian Li, and Huayi Suo

1. Introduction

Ulcerative colitis (UC) is a type of inflammatory bowel disease (IBD) [1] which is a non-specific chronic inflammation of the intestine including immune disorders, genetic predisposition, environmental factors, and certain lifestyle deprivations [2–4]. Common clinical symptoms are weight loss, abdominal pain, diarrhoea, and haematochezia. Although much progress has been made to categorize the complexity of IBD pathogenesis, its exact etiology is not clearly known, and there is no known cure currently available for this disease [5].

Dozens of different mouse models of colitis have been developed in order to study potential mechanisms of IBD pathogenesis and evaluate therapeutic effects. Among various different kinds of chemicals used to make colitis models, dextran sulfate sodium (DSS)-induced colitis is a widely used...
model because of its simplicity and many similarities with human UC. DSS is a highly water-soluble compound which is toxic for the colonic epithelial cells and causes defects in the epithelial barrier integrity, resulting in increased colonic epithelial permeability. Further, its anticoagulant property aggravates intestinal bleeding. Generally, DSS molecular weight is very critical for the severity of colitis; lower molecular weight (5 kDa) may result in milder colitis, while higher molecular weight (500 kDa) does not cause any injury to the colon. Therefore, a molecular weight of 36–50 kDa is used to induce colitis [6].

Probiotics can compete with pathogenic bacteria for mucosal adherence and simultaneously heal impaired mucosa; they can inhibit apoptosis, stimulate crypt cell proliferation, and regulate inflammatory cytokine expression as well as the intestinal immune system [7–10]. Therefore, the idea of using probiotics to cure IBD has attained specific importance. Numerous studies have demonstrated that the intestinal microbiota is significantly different between IBD patients/mice and healthy humans/mice; e.g., *Lactobacilli*, *Bifidobacterium*, *Streptococcus*, *Enterococcus*, *Fuso bacteria*, *Bacteroides* [11,12]. In addition, microbial dysbiosis in the gut can affect the synthesis and release of different inflammatory indicators, including pro-inflammatory cytokines such as tumor necrosis factor-α (TNF-α), IL-1β, Interferon-γ (IFN-γ), interleukin-1, 2, 6, 12 (IL-1, 2, 6, 12), anti-inflammatory cytokines (IL-4, IL-10), reactive oxygen and nitrogen metabolites, eicosanoids, and platelet activating factor [13].

Traditional fermented yak yogurt—a popular milk product in the Qinghai-Tibet plateau area, China—contains abundant lactic acid bacteria (LAB). We separated the dominant LAB strains from Xueo (traditional fermented yak milk brought from the western Sichuan Plateau of China); we took some genes from *Enterococcus durans*, *Lactobacillus fermentum*, and *Lactobacillus paracasei* using 16S rDNA sequence analysis and *atpA* gene analysis [14]. According to a survey of the composition of the microbiota in fermented yak milk at different Tibetan altitudes, *Lactobacillus fermentum* is the predominant lactic species in fermented milk [15]. Zhang showed that LAB dominate the kurut (naturally fermented yak milk) samples taken from the yaks of the plateau of the northwest and east of Qinghai, while yeast dominated in kurut samples from Huanhu yaks from the south of Qinghai [16]. In addition, there were six genera (*Lactobacillus*, *Lactococcus*, *Leuconostoc*, *Streptococcus*, *Enterococcus*, and *Weissella*) and twenty-one species of LAB existing in yak milk products in the Gansu Province of China. Due to the distinct climate conditions of the Qinghai-Tibet plateau, the living habits of herdsmen, yak milk varieties, and fermentation conditions such as temperature and time, LAB from yak yoghurt is superior and contains many unique properties [17]. *Lactobacillus fermentum* Suo was isolated and extracted from yak yoghurt of Hongyuan (Sichuan, China), which has better qualities of acid-resistance, bile tolerance, hydrophobic property, and preventive effects, as well against activated carbon-induced constipation in mice [18]. *Lactobacillus helveticus* H9 was isolated from traditionally fermented milk in Tibet (China); it has the ability to produce the antihypertensive peptides Val-Pro-Pro and Ile-Pro-Pro during milk fermentation [19]. The results of the experiment in vitro showed that the two *Lactobacilli* strains (*Lactobacillus coryniformis* subsp. torquens T3L and *Lactobacillus paracasei* subsp. paracasei M5L) isolated from traditionally fermented milk exhibit immunomodulating capacity [20]. *Lactobacillus fermentum* HY01 (LF-HY01) was also isolated from traditionally fermented yak yoghurt. The aim of this study was to assess the preventive effects of LF-HY01 to colitis using DSS-induced colitis mice model.

2. Materials and Methods

2.1. Strain

*Lactobacillus fermentum* HY01 (LF-HY01) was isolated from traditional fermented yak yoghurt of Hongyuan grassland houseland (Ngawa Tibetan and Qiang Autonomous Prefecture, Aba, Sichuan, China), and it was deposited in the China Center for the Type Culture Collection (CCTCC, Wuhan, China), bearing CCTCC Accession Number M2015792.
2.2. Animals

Forty mice from Kunming (six weeks old) with half males and half females were purchased from the Experimental Animal Center of Chongqing Medical University (Chongqing, China). Animal permit number: SYXK (Yu) 2012–0001. The mice were exposed to the conditions (temperature 25 ± 2 °C, relative humidity 50% ± 5%, 12 h light/12 h dark cycle), and free access to a standard mice chow diet and water.

2.3. Isolated and Identified

LF-HY01 was isolated from traditional fermented yak yoghurt using the serial dilution and spread plate method and cultured at 37 °C for 48 h in MRS both (BD, Franklin Lakes, NJ, USA); the MRS solid medium contained 1.5% agar. The cell morphology was observed after gram staining, and the genus was analyzed using 16S rDNA sequence and phylogenetic tree. Firstly, the genome DNA from LF-HY01 was extracted by TIANamp bacteria DNA kit (Tiangen, Beijing, China), its 16S rDNA was amplified with S1000 Thermal Cycler (Bio-Rad, Hercules, CA, USA), and the amplification product was tested by using 1.5% agarose gel electrophoresis. Finally, the remaining amplification product was sent to sequence (BGI, Shenzhen, Guangdong, China). Finally, based on 16S rDNA sequence of LF-HY01 and reference strains, a phylogenetic tree was built by using MEGA 5.05. During the experiment, LF-HY01 was activated and cultured at 37 °C for 18 h in MRS both.

2.4. Survival Rate in Simulated Gastric Juice

Stimulated gastric juice (100 mL) was composed of pepsin (0.35 g) and NaCl (0.2 g). The pH value of the solution was adjusted to pH 3 with 1 mol/L HCl using a pH meter (pHS-3C, Shanghai Lei Ci Instrument Factory, Shanghai, China) and sterilized by filtering through a 0.45 μm filter (Millipore, Billerica, MA, USA). Ten-milliliter inoculums were centrifuged at 4000 r/min for 10 min, washed twice with 10 mL sterilizing saline (0.9%), then resuspended in the same buffer. One milliliter of the suspension was mixed with 9 mL stimulated gastric juice and incubated in a shaking incubator (37 °C, 150 r/min) for 3 h. After that, its colony forming units (CFU) was separately counted at 0 and 3 h. The survival rate (SR) was calculated using the following equation: SR (%) = \( \frac{N_3}{N_0} \times 100 \), where SR is the survival rate of Lactobacillus and \( N_0 \) is the number of viable cells (CFU/mL) at 0 h and \( N_3 \) is the number of viable cells (CFU/mL) at 3 h [20].

2.5. Bile Salt Tolerance

One-hundred microliter inoculums were inoculated into 5 mL MRS-THIO (MRS broth plus 0.2% of sodium thioglycolate) with or without 0.3% (w/v) oxgall. Bacterial cell in the culture broth was measured by reading the optical density (OD) at 600 nm after 24 h incubation at 37 °C. The percentage of bile tolerance was calculated using the following equation: BT (%) = \( \frac{A}{A_0} \times 100 \), where BT is the bile tolerance of Lactobacillus, A is the OD of bacterial cell with 0.3% (w/v) oxgall, and \( N_0 \) is the OD of bacterial cell without 0.3% (w/v) oxgall [20].

2.6. Induction of Colitis in Mice

To study the preventive effects of Lactobacillus fermentum HY01 against DSS-induced colitis, the animals were divided into four groups with five females and five males in each group. The experimental design was as follows: the normal group mice (N) was fed a normal diet and drank water from weeks 1 to 5. The model group (DSS) was fed a normal diet and drank water during the experiment, but drank water with 2% (w/v) DSS (molecular mass, 40 kDa; ICN Biomedicals, Aurora, OH, USA) in the third week and 4% DSS in the fifth week. The low- and high-dose groups were gavaged with \( 10^9 \) CFU/kg-bw and \( 10^{10} \) CFU/kg-bw in weeks 1 to 5. Ten milliliter inocula were centrifuged at 4000 r/min for 10 min, washed twice with 10 mL 0.9% sterilizing saline and resuspended in 10 mL 0.9% sterilizing saline. We then determined colony counts by using plate colony-counting.
method and its absorbance at 600 nm by using the spectrophotometer. During this experiment, we used the results of colony counts and absorbance to adjust the certain concentration of LF-HY01 to gavage. The fresh inoculum was prepared once a day. In addition, low- and high-dose groups were fed a normal diet and drank water during the experiment, but drank water with 2% DSS in the third week and 4% DSS in the fifth week.

2.7. Collection of Samples

After 5 weeks, the mice were killed. We quickly measured the length and weight of the colon and took photos, then a portion of colon was used to make HE slice and the rest was stored at −80 °C after liquid nitrogen refrigeration to measure the levels of proteins. The serum was isolated (4 °C, 3000 r/min, 10 min) and stored at −80 °C.

2.8. Histological Observations

The colons were immediately removed after sacrificing and fixed in 10% (v/v) buffered formaldehyde, paraffin embedded, sectioned, followed by hematoxylin and eosin staining.

2.9. Measurement of Cytokine in the Serum

The concentrations of IFN-γ, IL-12, TNF-α, and IL-6 in the serum were measured by enzyme-linked immunosorbent assay kits (Beijing Bai Ao Lai Bo Co., Ltd., Beijing, China).

2.10. Western Blot Analysis

Proteins were extracted and analyzed by general Western blot protocol. Just for a brief period, proteins were extracted by RIPA buffer (R0010, Solarbio, Beijing, China) with 12,000 r/min centrifugation for 5 min and subjected to SDS-PAGE and transferred to 0.45 µm PVDF membranes (Millipore, Billerica, MA, USA). Membranes were blocked for 2 h at room temperature with 5% BSA, then incubated overnight at 4 °C with appropriate dilutions of primary antibodies (Abcam, Cambridge, UK), five washes with TBST, having 5 min each. This was then followed by incubation of membrane with conjugated secondary antibody (Abcam, Cambridge, UK) for 1 h at room temperature, and three washes with TBST at 5 min each. Finally,

2.11. Statistical Analysis

Data are presented as mean ± standard deviation, and the differences were evaluated using analysis of variance (ANOVA) with Duncan’s multiple range tests. P < 0.05 was considered statistically significant. The analysis was performed with SPSS 17.0 (IBM, Armonk, NY, USA).

3. Results

3.1. Strain

LF-HY01 colonial morphology was consistent (Figure 1a), and cells were all rod shaped (Figure 1b). The electrophoresis result of 16S rDNA amplification product from LF-HY01 was satisfactory with clear band, correct place, and non-specific amplification (Figure 1c). After analyzing by 16S rDNA sequence and phylogenetic tree, the results of both the analyzing methods were consistent, and LF-HY01 was considered to be Lactobacillus fermentum. The specific results were that LF-HY01 had 100% homology with Lactobacillus fermentum, and LF-HY01 gathered together with Lactobacillus fermentum in the Lactobacillus branch (Figure 1d).
3.2. In Vitro Characteristics of Strain

The effect of stimulated gastric juice and different concentrations of bile salt can change the viability of LF-HY01 as presented in Table 1. LF-HY01 exhibited complete tolerance to simulated gastric juice, and its growth efficiency in bile salt decreased with the increase in bile salt concentration, but it still had its function in a very high level 0.3% bile salt as well.

| Strain   | Survival in PH 3.0 Simulated Gastric Juice (%) | Growth Efficiency in Bile Salt (%) |
|----------|-----------------------------------------------|-----------------------------------|
|          |                                               | 0.05  | 0.1  | 0.2  | 0.3  |
| LF-HY01  | 103.73 ± 8.60                                 | 98.30 ± 0.09 | 61.50 ± 0.45 | 29.40 ± 0.80 | 21.62 ± 0.86 |

3.3. Colon Weight and Length

Shortening of the colon is one of the typical symptoms of colitis [21]. As shown in Figure 2a,b, the colon length was noticeably short in DSS-treated mice (9.08 ± 0.83 cm) than in normal mice (13.06 ± 1.43 cm). After being treated with different doses of LF-HY01, it was noticed that it had the ability to effectively alleviate the colon length, but the treatment had better effects with moderate dose. The colon length with low- and high-dose treatment was 10.90 ± 1.04 cm and 12.18 ± 1.33 cm, respectively. We know that edema is one of the typical symptoms of colitis [22]. The ratio of colon weight to colon length is generally used to indirectly understand edema extent (the larger the ratio, the more serious the edema). As shown in Figure 2c, the ratio of colon weight to colon length (mg/cm) was significantly increased in DSS-treated mice (46.84 ± 2.40 mg/cm) as compared to that of normal mice (35.55 ± 0.89 mg/cm). The ratio of different doses of LF-HY01-treated mice had a very significant difference with DSS-treated mice, but remarkably had a slight difference with normal mice, so it was proved that different doses of LF-HY01 treatment could remit the colon tissue edema.
Figure 2. Colon length and weight of colitis mice. (a) Morphological observation of colon in mice; (b) Colon length in mice; (c) Colon weight/length in mice. N (normal group), dextran sulfate sodium (DSS, model group), L (low dose group, \(10^9\) CFU/kg bw), H (high dose group, \(10^{10}\) CFU/kg bw); a,b,c expressed as significant level, \(p < 0.05\).

3.4. Histological Analyses

The hematoxylin and eosin-stained sections were observed under microscope to evaluate the preventive effects in mice that were treated with LF-HY01 and had DSS-induced colitis. As is evident in Figure 3, the tissue sections of normal mice—as compared to that of the DSS-treated mice—showed colonic mucosal damage, decreased goblet cells, aberrant crypts, and considerable inflammatory cells infiltrations. However, the structure of tissue sections taken from LF-HY01-treated mice with different doses that had DSS-induced colitis was found almost normal; they had more intact colonic mucous epithelium, crypt glands, and less inflammatory reactions than those in the DSS-colitis mice. The results indicate that LF-HY01 can reduce colitis symptoms to a very great extent in DSS induced-colitis.

3.5. IL-6, IL-12, INF-\(\gamma\), and TNF-\(\alpha\) Concentrations in Serum

Cytokines are low molecular weight proteins which can induce or regulate a variety of immune or inflammatory responses, and play a critical role as a host. IL-6, IL-12, INF-\(\gamma\), and TNF-\(\alpha\) are all pro-inflammatory [23]. As shown in Figure 4a–d, the IL-6, IL-12, INF-\(\gamma\), and TNF-\(\alpha\) concentrations of normal mice were lowest. The concentrations of these cytokines were highest in the DSS-colitis mice. All these cytokine concentrations in serum were significantly decreased after the treatment of different doses of LF-HY01—especially the moderate dose, which did not differ much from the normal mice.
Figure 3. Histopathology observation of colon. N (normal group), DSS (model group), L (low dose group, $10^9$ CFU/kg·bw), H (high dose group, $10^{10}$ CFU/kg·bw).

Figure 4. Pro-inflammatory factors concentrations in serum. (a) IL-6 cytokine level in serum; (b) IL-12 cytokine level in serum; (c) TNF-α cytokine level in serum; (d) IFN-γ cytokine level in serum. N (normal group), DSS (model group), L (low dose group, $10^9$ CFU/kg·bw), H (high dose group, $10^{10}$ CFU/kg·bw); $a$, $b$, $c$ expressed as significant level, $p < 0.05$. TNF-α: Tumor necrosis factor-α; IFN-γ: interferon-γ; IL-6, 12: interleukin-6, 12.
3.6. Western Blot

IκBα, NF-κB p65, iNOS, and COX-2 as determined by Western blot are shown in Figure 5a–d. DSS treatment concentration could significantly decrease the level of IκBα and increase the level of NF-κB p65, iNOS, and COX-2. However, LF-HY01 could increase the level of IκBα and decrease the levels of NF-κB p65, iNOS, and COX-2 in DSS-colitis mice.

![Figure 5: Protein levels in colon. (a) Semiquantitative analysis of protein ratio IκBα/β-actin; (b) Semiquantitative analysis of protein ratio NF-κB p65/β-actin; (c) Semiquantitative analysis of protein ratio iNOS/β-actin; (d) Semiquantitative analysis of protein ratio COX-2/β-actin. N (normal group), DSS (model group), L (low dose group, 10⁹ CFU/kg bw), H (high dose group, 10¹⁰ CFU/kg bw); a,b,c expressed as significant level, p < 0.05.](image)

4. Discussion

Probiotics are recognized as live microorganisms which confer health benefit to the host when administered in adequate amount, so as to maintain the balance of the intestinal microbiota and enhance immunity [24]. Most probiotic strains are *Lactobacilli* which were isolated from infant, healthy adult, or fermented foods, generally evaluated by different selection criteria, which include: withstand transit through the gastrointestinal tract, the capacity to inhibit intestinal pathogens, the ability to colonize the intestinal tract, health benefits, etc. However, only probiotic strains surviving through the passage of the stomach and the small intestine have full scope to give the health benefits to the host [25,26]. Therefore, resisting gastric juice and bile salts in the gastrointestinal tract is the fundamental requirement [18]. In this study, based on an external virtual model of the gastrointestinal tract, we defined that LF-HY01 was not affected at pH 3.0 simulated gastric juice, and also had the
ability to keep good growth efficiency in different concentrations of bile salts. This indicates that LF-HY01 was suitable for the study purpose based on functional effects associated with health benefits.

Generally speaking, colon length, colon edema, and mucosal damage are useful indices to evaluate the degree of inflammation; they are typical symptoms of colitis. When the colon length is shorter, the symptoms (colon edema, mucosal damage) are also more serious, and the most severe is inflammation [21,27]. For example, shortening of the colon, edema, and bleeding are macroscopic appearances in the TNBS-induced colitis mouse model [28]. In the same way, the macroscopic appearances were same in the DSS-induced colitis mouse model [29]. In this study, we observed shortening of the colon, edema, and bleeding after the injuries induced by DSS, and treatment with LF-HY01 could not only relieve shortened colon and reduce the ratio of colonic weight to length, but also prevented mucosal damage, helped to increase goblet cells, and remitted inflammatory cells infiltration. Therefore, we speculated that LF-HY01 may improve the healthy functioning of the intestinal mucosa.

Cytokines play an important role in the modulation of the immune system, which contains anti-inflammatory cytokines factors and pro-inflammatory cytokines factors in the inflammatory response, and which are related to Th1 or Th2 cells. Orchestrating cell-mediated immunity is the key ability of Th1 cells, and they can secrete INF-\(\gamma\), IL-2, and IL-12. In contrast, mediating humoral responses is the key ability of Th2 cells, and they can secrete IL-4, IL-5, IL-6, IL-10, and IL-13. These subsets can regulate each other reciprocally through key cytokines. INF-\(\gamma\) can suppress the development of Th2, whereas IL-4, IL-10, and IL-13 secreted by Th2 cells inhibit Th1 responses, and the effect of regulating each other maintains normal state. During the period of inflammation, this adjustable effect was damaged, hence promoting inflammation. INF-\(\gamma\), IL-12, TNF-\(\alpha\), and IL-6 are all pro-inflammatory cytokines which can cause immune disorders and amplify the inflammation. INF-\(\gamma\) is a dimeric glycoprotein, and it can badly affect the structure and function of intestinal epithelial cells and increase the permeability of intestinal mucosa [30]. IL-12 can not only promote the differentiation of Th0 cells into Th1 cells and the production of IL-2 and IFN-\(\gamma\), it can also inhibit the differentiation of Th0 cells into Th2 cells and the synthesis of IgE [28]. TNF-\(\alpha\) is the earliest and most important inflammatory mediator; it can gather immunological cells and lead to inflammatory cells infiltration and tissue edema [31]. IL-6 can promote the synthesis of acute protein and gather T cells in inflammatory sites [32]. In this study, we demonstrated that IFN-\(\gamma\), IL-12, TNF-\(\alpha\), and IL-6 increase in DSS-induced colitis mice. However, the concentrations of IFN-\(\gamma\), IL-12, TNF-\(\alpha\), and IL-6 decrease after LF-HY01 treatment.

In addition, probiotics could inhibit activated NF-\(\kappa\)B [33]. NF-\(\kappa\)B is a nuclear transcription factor which can regulate many genes, apoptosis, viral replication, tumorigenesis, and inflammation. NF-\(\kappa\)B was normally inactive in the form of p50-p65-I\(\kappa\)B\(\alpha\), because it was inhibited by I\(\kappa\)B\(\alpha\). However, under some conditions (growth factors, cytokines, lymphokines, UV, pharmacological agents, and stress), I\(\kappa\)B\(\alpha\) is ubiquitinated and phosphorylated, causing the activation of NF-\(\kappa\)B. This result would accentuate inflammation with the creation of adhesion molecules, transcription factors, inflammatory cytokines, and cell surface receptors in the end. Furthermore, NF-\(\kappa\)B has the transcription regulation genes iNOS and COX-2, so it can regulate the expression of iNOS and COX-2 inflammatory proteins. When NF-\(\kappa\)B is activated, the protein levels of iNOS and COX-2 increase. iNOS is a messenger molecule with diverse functions throughout the body; it can produce nitric oxide (NO), which has the ability to relax blood vessels and raise the vessel permeability. Thus, it has advantages of the inflammation medium to reach inflammatory sites and leads to inflammation aggravation. COX-2 is an inducible enzyme which is hardly expressed in normal body, but its level is up-regulated in response to body damage during colitis. COX-2 is known to synthesize prostaglandins (PGs) from arachidonic acid, which is associated with the mediation of colitis. Furthermore, it has been reported that the expression levels of COX-2 and PGE2 were elevated in the inflamed mucosal tissues of patients/mice with colitis. Above all, these results eventually promoted the secretion of intestinal epithelial cells, caused edema, expanded blood vessels, and increased permeability of the intestinal mucosa [23]. In this study, we
used DSS-induced colitis, and we observed an increase in NF-κB p65 protein levels and a decrease in IkBα protein levels. Moreover, we also found the protein levels of iNOS and COX-2 increased. After LF-HY01 treatment, we observed a decrease in NF-κB p65 protein levels and an increase in IkBα protein levels, and we also found reduced protein levels of iNOS and COX-2. It has been shown that LF-HY01 directly inhibited the expression of NF-κB-dependent cytokines by suppressing the activators of pro-inflammatory cytokines (iNOS and COX-2) [23], and thus reduced inflammation. Previous studies showed that probiotics can significantly improve intestinal immune function, so probiotics can directly or indirectly regulate intestinal immune response [11]. *Lactobacillus fermentum* 5716 can reduce TNF-α levels and iNOS expression in the TNBS model [34]. *Lactobacillus brevis* HY7401 and *Lactobacillus plantarum* HY115 could inhibit colon shortening, suppressed the mRNA expressions of IL-1β, IFN-γ, and TNF-α, and also the protein levels of IL-1β and IL-6 in the colon of DSS-induced colitic mice. Therefore, these results suggested LF-HY01 could improve colitis in this study. In this study, LF-HY01 could prevent IkBα degradation, inhibit NF-κB p65 phosphorylation cascades, and reduce the protein levels of iNOS and COX-2. Therefore, LF-HY01 had the advantages of preventing the effects of colitis. However, how to regulate immune response of LF-HY01 is still unclear, so it is very important to further evaluate its mechanism of preventing colitis, because this can provide the basic theories for the functional application of LF-HY01.

5. Conclusions

*Lactobacillus fermentum* has been known as a probiotic. *Lactobacillus fermentum* HY01 (LF-HY01) which was isolated from traditional fermented yak yoghurt had good acid resistance, bile tolerance, and preventive effects for colitis. The preventive effects included improving colon cells as well as length damage, lowering the concentrations of pro-inflammatory factors (INF-γ, IL-12, TNF-α, and IL-6), increasing the protein levels of IkBα, and decreasing the protein levels of NF-κB p65, iNOS, and COX-2.

Acknowledgments: This work was partly supported by Special Fund for Agro-scientific Research in the Public Interest (201303085), the People’s Livelihood Science and technology innovation Foundation of Chongqing (cstc2015shmszx80021), Fundamental Research Funds for the Central Universities (XDJK2016A018), the Construction Program of Chongqing Collaborative Innovation Center for Functional Food, Chongqing University of Education (167001) and Chongqing Research Program of Basic Research and Frontier Technology (cstc2016jcyjA0820), China.

Author Contributions: Xiaoyong Chen and Xin Zhao performed the majority of the experiments and wrote the manuscript; Hongwei Wang and Zelin Yang contributed to the data analysis; Jian Li and Huayi Suo designed and supervised the study and checked the final manuscript.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Zbakh, H.; Talero, E.; Avila, J.; Alcaide, A.; Reyes, C.; Zubia, E.; Motilva, V. The algal meroterpenoid 11-hydroxy-1′-o-methylamentadione ameliorates dextran sulfate sodium-induced colitis in mice. *Mar. Drugs* 2016, 14, 149. [CrossRef] [PubMed]
2. Leone, V.; Chang, E.B.; Devkota, S. Diet, microbes, and host genetics: The perfect storm in inflammatory bowel diseases. *J. Gastroenterol.* 2013, 48, 315–321. [CrossRef] [PubMed]
3. Carbonnel, F.; Jantchou, P.; Monnet, E.; Cosnes, J. Environmental risk factors in Crohn’s disease and ulcerative colitis: An update. *Gastroenterol. Clin. Biol.* 2009, 33, S145–S157. [CrossRef]
4. Buttol, L.F.; Haller, D. Dysbiosis in intestinal inflammation: Cause or consequence. *Int. J. Med. Microbiol.* 2016, 306, 302–309. [CrossRef] [PubMed]
5. Chassaing, B.; Aitken, J.D.; Malleshappa, M.; Vijay-Kumar, M. Dextran sulfate sodium (DSS)-induced colitis in mice. *Curr. Protoc. Immunol.* 2014, 104, 15–25.
6. Perse, M.; Cerar, A. Dextran sulphate colitis mouse model: Traps and tricks. *J. Biomed. Biotechnol.* 2012, 2012, 718617. [CrossRef] [PubMed]
7. Geier, M.S.; Butler, R.N.; Giffard, P.M.; Howarth, G.S. Lactobacillus fermentum BR11, a potential new probiotic, alleviates symptoms of colitis induced by dextran sulfate sodium (DSS) in rats. *Int. J. Food Microbiol.* 2007, 114, 267–274. [CrossRef] [PubMed]

8. Rochat, T.; Bermúdez-Humarán, L.; Gratadoux, J.; Fourage, C.; Hoebler, C.; Corthier, G.; Langella, P. Anti-inflammatory effects of *Lactobacillus casei* BL23 producing or not a manganese-dependant catalase on DSS-induced colitis in mice. *Microb. Cell Fact.* 2007, 6, 1–10. [CrossRef] [PubMed]

9. Song, J.L.; Qian, Y.; Li, G.J.; Zhao, X. Anti-inflammatory effects of *Lactobacillus casei* Tseng in dextran sulfate sodium-induced ulcerative colitis. *Mol. Med. Rep.* 2013, 8, 1256–1262. [PubMed]

10. Zhu, T.; Wang, D.; Zhang, W.; Liao, X.; Guan, X.; Bo, H.; Sun, J.; Huang, N.; He, J.; Zhang, Y.; et al. Andrographolide protects against LPS-induced acute lung injury by inactivation of NF-kappa B. *PLoS ONE* 2013, 8, e56407.

11. Orel, R. Intestinal microbiota, probiotics and prebiotics in inflammatory bowel disease. *World J. Gastroenterol.* 2014, 20, 11505–11524. [CrossRef] [PubMed]

12. Macfarlane, S.; Furrie, E.; Cummings, J.H.; Macfarlane, G.T. Chemotaxonomic analysis of bacterial populations colonizing the rectal mucosa in patients with ulcerative colitis. *Clin. Infect. Dis.* 2004, 38, 1690–1699. [CrossRef] [PubMed]

13. Liu, Y.; Su, Y.; Ong, W.; Cheng, T.; Tsai, Y. Oral administration of *Lactobacillus plantarum* K68 ameliorates DSS-induced ulcerative colitis in BALB/c mice via the anti-inflammatory and immunomodulatory activities. *Int. Immunopharmacol.* 2011, 11, 2159–2166. [CrossRef] [PubMed]

14. Bao, Q.; Yu, J.; Liu, W.; Qing, M.; Wang, W.; Chen, X.; Wang, F.; Li, M.; Wang, H.; Lv, Q.; et al. Predominant lactic acid bacteria in traditional fermented yak milk products in the Sichuan Province of China. *Dairy Sci. Technol.* 2012, 92, 309–319. [CrossRef]

15. Liu, W.; Xi, X.; Sudu, Q.; Kwok, L.; Guo, Z.; Hou, Q.; Menhe, B.; Sun, T.; Zhang, H. High-throughput sequencing reveals microbial community diversity of Tibetan naturally fermented yak milk. *Ann. Microbiol.* 2015, 65, 1741–1751. [CrossRef]

16. Ao, X.; Zhang, X.; Zhang, X.; Shi, L.; Zhao, K.; Yu, J.; Dong, L.; Cao, Y.; Cai, Y. Identification of lactic acid bacteria in traditional fermented yak milk and evaluation of their application in fermented milk products. *J. Dairy Sci.* 2012, 95, 1073–1084. [CrossRef] [PubMed]

17. Zhang, H. Biodiversity of *Lactic acid bacteria* in naturally fermented dairy products. *Chinese Bull. Life Sci.* 2015, 7, 837–846.

18. Suo, H.; Zhao, X.; Qian, Y.; Li, G.; Liu, Z.; Xie, J.; Li, J. Therapeutic effect of activated carbon-induced constipation mice with *Lactobacillus fermentum* Suo on treatment. *Int. J. Mol. Sci.* 2014, 15, 21875–21895. [CrossRef] [PubMed]

19. Chen, Y.; Liu, W.; Xue, J.; Yang, J.; Chen, X.; Shao, Y.; Kwok, L.Y.; Bilige, M.; Mang, L.; Zhang, H. Angiotensin-converting enzyme inhibitory activity of *Lactobacillus helveticus* strains from traditional fermented dairy foods and antihypertensive effect of fermented milk of strain H9. *J. Dairy Sci.* 2014, 97, 6680–6692. [CrossRef] [PubMed]

20. Tuo, Y.; Zhang, L.; Xue, H.; Ming, D. In vitro assessment of immunomodulating activity of the two *Lactobacillus* strains isolated from traditional fermented milk. *World J. Microb. Biol.* 2011, 27, 505–511. [CrossRef]

21. Song, J.; Choi, J.; Seo, J.; Lim, Y.; Park, K. Anti-Colitic effects of Kanjongs (fermented soy sauce and sesame sauce) in dextran sulfate sodium-induced colitis in mice. *J. Med. Food* 2014, 17, 1027–1035. [CrossRef] [PubMed]

22. Senol, A. Kefir treatment ameliorates dextran sulfate sodium-induced colitis in rats. *World J. Gastroenterol.* 2015, 21, 13020–13029. [CrossRef] [PubMed]

23. Pandurangan, A.K.; Mohebali, N.; Esa, N.M.; Looi, C.Y.; Ismail, S.; Saadatdoust, Z. Gallic acid suppresses inflammation in dextran sodium sulfate-induced colitis in mice: Possible mechanisms. *Int. Immunopharmacol.* 2015, 28, 1034–1043. [CrossRef] [PubMed]

24. Presti, I.; D’Orazio, G.; Labra, M.; La Ferla, B.; Mezzasalma, V.; Bizzarro, G.; Giardina, S.; Michelotti, A.; Tursi, F.; Vassallo, M.; et al. Evaluation of the probiotic properties of new *Lactobacillus* and *Bifidobacterium* strains and their in vitro effect. *Appl. Microbiol. Biol.* 2015, 99, 5613–5626. [CrossRef] [PubMed]
25. Barrangou, R.; Altermann, E.; Hutkins, R.; Cano, R.; Klaenhammer, T.R. Functional and comparative genomic analyses of an operon involved in fructooligosaccharide utilization by *Lactobacillus acidophilus*. *Proc. Natl. Acad. Sci. USA* 2003, 100, 8957–8962. [CrossRef] [PubMed]

26. Nishida, S.; Michinaka, A.; Nakashima, K.; Iino, H.; Fuji, T. Evaluation of the probiotic potential of *Lactobacillus paracasei* KW3110 based on in vitro tests and oral administration tests in healthy adults. *J. Gen. Appl. Microbiol.* 2008, 54, 267–276. [CrossRef] [PubMed]

27. Fang, K.; Bruce, M.; Pattillo, C.B.; Zhang, S.; Stone, R.; Clifford, J.; Kevil, C.G. Temporal genomewide expression profiling of DSS colitis reveals novel inflammatory and angiogenesis genes similar to ulcerative colitis. *Physiol. Genomics* 2011, 43, 43–56. [CrossRef] [PubMed]

28. Duary, R.K.; Bhausaheb, M.A.; Batish, V.K.; Grover, S. Anti-inflammatory and immunomodulatory efficacy of indigenous probiotic *Lactobacillus plantarum* Lp91 in colitis mouse model. *Mol. Biol. Rep.* 2012, 39, 4765–4775. [CrossRef] [PubMed]

29. Vowinkel, T.; Kalogeris, T.J.; Mori, M. Impact of dextran sulfate sodium load on the severity of inflammation in experimental colitis. *Digest. Dis. Sci.* 2004, 49, 556–564. [CrossRef]

30. Zingoni, A.; Sornasse, T.; Cocks, B.G.; Tanaka, Y.; Santoni, A.; Lanier, L.L. Cross-talk between activated human NK cells and CD4+ T cells via OX40–OX40 ligand interactions. *J. Immunol.* 2004, 173, 3716–3724. [CrossRef] [PubMed]

31. Ishiguro, K.; Ando, T.; Maeda, O.; Watanabe, O.; Goto, H. Novel mouse model of colitis characterized by hapten-protein visualization. *Biotechniques* 2010, 49, 641–648. [CrossRef] [PubMed]

32. Grivennikov, S.; Karin, E.; Terzic, J.; Mucida, D.; Yu, G.Y.; Vallabhapurapu, S.; Scheller, J.; Rose-John, S.; Cheroutre, H.; Eckmann, L., et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. *Cancer Cell* 2009, 15, 103–113. [CrossRef] [PubMed]

33. Lee, H.; Han, S.; Bae, E.; Huh, C.; Ahn, Y.; Lee, J.; Kim, D. Lactic acid bacteria inhibit proinflammatory cytokine expression and bacterial glycosaminoglycan degradation activity in dextran sulfate sodium-induced colitic mice. *Int. Immunopharmacol.* 2008, 8, 574–580. [CrossRef] [PubMed]

34. Peran, L.; Camuesco, D.; Comalada, M.; Nieto, A.; Concha, A.; Adrio, J.I.; Olivares, M.; Xaus, J.; Zarzuelo, A.; Galvez, J. *Lactobacillus fermentum*, a probiotic capable to release glutathione, prevents colonic inflammation in the TNBS model of rat colitis. *Int. J. Colorectal Dis.* 2006, 21, 737–746. [CrossRef] [PubMed]

© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).